Expert Interview
Q3 #2: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Ticker(s): BIIB, ESAIY- board-certified neurologist with Global Neurosciences Institute, where he serves as Director of their Neuro-Hospitalist Program and Director of Medical Student Education
- Treats 74 patients with Alzheimer's Disease
- Has prescribed Lequembi
- specializes in stroke treatment and has subspecialty board certifications in Vascular Neurology, Headache Medicine, and Brain Injury Medicine
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
